447 / 1851
DAHANCA 10 randomized phase III
LARYNX, PHARYNX* and ORAL CAVITY
T1-4,N0-3, M0
(not st 1 glottic larynx)
RANDOMIZE
Acclerated RT (6 fx/week)
(66-68 Gy/33-34 fx)
+ Hypoxic sensitizer:
Nimorazol
* Except NPC
Aranesp®
(darbepoetin alpha
)
Weekly subcutaneously
injection
Stratify by:
Gender
Site
T&N stage
WHO perf.
Institution
Low hemoglobin value: <
9.0 mmol/l (14.5 g/dl).
+
Acclerated RT (6 fx/week)
(66-68 Gy/33-34 fx)
+ Hypoxic sensitizer:
Nimorazol
Overgaard et al ICHNO 2013